Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro.

Sarkaria, S M; Christopher, M J; Klco, J M; Ley, T J

Sarkaria, S M; Christopher, M J; Klco, J M; Ley, T J.

Afiliação

Sarkaria SM; Section of Stem Cell Biology, Division of Oncology, Department of Internal Medicine, Washington University in St Louis School of Medicine, St Louis, MO, USA.
Christopher MJ; Section of Stem Cell Biology, Division of Oncology, Department of Internal Medicine, Washington University in St Louis School of Medicine, St Louis, MO, USA.
Klco JM; Department of Pathology and Immunology, Washington University in St Louis School of Medicine, St Louis, MO, USA.
Ley TJ; Section of Stem Cell Biology, Division of Oncology, Department of Internal Medicine, Washington University in St Louis School of Medicine, St Louis, MO, USA.

Leukemia ; 28(12): 2403-6, 2014 Dec.

Article em En | MEDLINE | ID: mdl-25092143

Assuntos

Adenosina/análogos & derivados; Isocitrato Desidrogenase/genética; Leucemia Mieloide Aguda/genética; Metiltransferases/antagonistas & inibidores; Mutação; Compostos de Fenilureia/farmacologia; Adenosina/farmacologia; Proliferação de Células/efeitos dos fármacos; Histona-Lisina N-Metiltransferase; Humanos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Leucemia Mieloide Aguda / Adenosina / Isocitrato Desidrogenase / Metiltransferases / Mutação Limite: Humans Idioma: En Revista: Leukemia Ano de publicação: 2014 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google